Question · asked by 1 review
Aciclovir (oral or intravenous) for treatment vs placebo: Length of hospital stay
- Population
- Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
- Intervention
- Aciclovir (oral or intravenous) for treatment
- Comparison
- placebo
- Outcome
- Length of hospital stay
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Aciclovir (oral or intravenous) for treatment vs Placebo Days stay in hospital · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients /… The review found no eligible studies for this question. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer (2009) · Cochrane All outcomes | For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life. | 0 studies | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes | 2008-11 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.